SAN DIEGO, Jan. 5 /PRNewswire/ -- SGX Pharmaceuticals, Inc. (SGX) today announced the appointment of W. Todd Myers, C.P.A., as Chief Financial Officer, and Siegfried Reich, Ph.D., as Vice President, Drug Discovery.
Todd Myers has more than 16 years of professional experience in finance, accounting, public offerings, venture and private equity financing, and SEC accounting and reporting. He most recently provided senior level financial consulting services to publicly traded and privately held life sciences companies. From 2000 to 2004, he served as Chief Financial Officer of FeRx Incorporated, an oncology development company. Todd has also held senior level finance positions at CombiChem, Inc. and Premier, Inc. and began his professional career at Ernst & Young, LLP. Todd earned his B.S. in Accounting from the University of Illinois.
Dr. Siegfried Reich will assume the position of Vice President, Drug Discovery on February 1, 2006. Prior to joining SGX, Siegfried was Vice President, Head of Viral and Ophthalmic Diseases Therapeutic Zone in Discovery, at Pfizer, Inc., where he was responsible for overseeing the delivery of multiple clinical candidates. Prior to that, he held senior scientific leadership positions at Agouron Pharmaceuticals, Inc., including serving as co-project leader of the HIV Protease project, which identified Viracept(R) for the treatment of AIDS. Siegfried received his Ph.D. in Chemistry from U.C. Irvine.
About SGX
SGX Pharmaceuticals (SGX) is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. More information can be found at www.sgxpharma.com.
SGX Pharmaceuticals, Inc.
CONTACT: Jason Spark of Atkins + Associates, +1-858-527-3491,jspark@irpr.com, for SGX Pharmaceuticals, Inc.
Web site: http://www.sgxpharma.com/